Nanobiotix Announces €75 Million Global Follow-On Offering of ADSs and Ordinary Shares

On May 20, 2026, Nanobiotix S.A. announced the launch of a global follow-on offering targeting approximately €75 million (roughly $87 million) in gross proceeds. The offering is structured in two parts: a public offering of American Depositary Shares (ADSs) in the United States and an international offering of ordinary shares and pre-funded warrants (PFW) to qualified investors in Europe and other select regions. The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered. Net proceeds are earmarked for three primary areas: less than 10% for the development of JNJ-1900 (NBTXR3), between 50-60% to advance the Nanoprimer and other technology platforms, and 30-40% for general corporate purposes. The final pricing and number of securities will be determined through a book-building process. Jefferies, TD Cowen, and Stifel are serving as global coordinators and joint bookrunners. Trading of the company's ordinary shares on Euronext Paris will be briefly suspended on May 21, 2026, pending the opening of ADS trading on Nasdaq.